MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.
← catalyst calendarNCT07607769 · readout in 804 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
24
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-16 | actual | When the study began enrolling |
| Primary completion | 2028-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma
Intervention
- Drug: STRIDE
Primary outcome
what the primary-completion date above is the date OFTime To Decompensation (TTDec)
measured From index date to first hepatic decompensation/study completion, up to 30 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed